Subscribe
Tupungato / Shutterstock.com
6 November 2025NewsBig PharmaMuireann Bolger

Pfizer can’t block Novo Nordisk’s $10bn takeover deal

Judge delivers major setback to pharma giant’s efforts to scupper rival’s surprise bid, in an increasingly bitter feud over an obesity drug biotech.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novo Nordisk counters rival with $9bn bid for obesity drug developer
30 October 2025   Danish pharma giant sweetens offer for hot peptide therapeutics company, aiming to cement its market position amid an intensifying GLP-1 patent race.


Editor's picks

New AIPLA president calls for greater certainty in US patent law
Americas
New AIPLA president calls for greater certainty in US patent law
6 November 2025

Editor's picks

Americas
New AIPLA president calls for greater certainty in US patent law
6 November 2025
Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025
Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
23 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025

More features

New AIPLA president calls for greater certainty in US patent law
Regeneron and CureVac: UPC ‘cannot be ignored’
US generics company wins patent battle over Merck Serono’s blockbuster MS drug
Novartis counsel warns: ‘Don’t let AI develop without our input’
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
Is Hatch-Waxman litigation for orphan drugs working?
Delegates descend upon Washington, DC for AIPLA Annual Meeting
Novo Nordisk counters rival with $9bn bid for obesity drug developer